Silverback Therapeutics SBTX

$ 6.1 4.99%

Quarterly report 2024-Q3
added 11-13-2024

Silverback Therapeutics Financial Statements 2011-2024 | SBTX

Annual Financial Statements Silverback Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	581 M	244 M	124 M	420 M	-	-	-	-	-	-	-	-	-
Shares	95.2 M	40 M	28.9 M	9.56 M	-	-	-	-	-	-	-	-	-
Historical Prices	6.1	6.1	4.3	48.1	-	-	-	-	-	-	-	-	-
Net Income	-54.4 M	-34.7 M	-20.2 M	-32.9 M	-24 M	-17.6 M	-	-	-	-	-	-	-
Revenue	30 K	1.32 M	5.51 M	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-67.5 M	-35.5 M	-19.5 M	-32.9 M	-	-	-	-	-	-	-	-	-
Interest Expense	13.2 M	974 K	-789 K	-29 K	-	-	-	-	-	-	-	-	-
EBITDA	-67.4 M	-35.4 M	-19.2 M	-32.3 M	-23.5 M	-17.8 M	-	-	-	-	-	-	-
Operating Expenses	67.6 M	36.8 M	25 M	32.9 M	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	47.3 M	18.5 M	4.69 M	8.34 M	2.56 M	3.52 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Silverback Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	97 M	96.8 M	96.5 M	96.4 M	95.6 M	94.9 M	94.2 M	93.9 M	30.8 M	30.6 M	30.4 M	35.1 M	35 M	34.9 M	34.8 M	34.7 M	678 K	670 K	669 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-19.1 M	-12.5 M	-10.3 M	-	-14.9 M	-17.4 M	-15 M	-	-6.58 M	-6.42 M	-7.25 M	-	-22.7 M	-24.5 M	-18.9 M	-	-8.12 M	-6.47 M	-5.28 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	2.07 M	500 K	-	-	-	10 K	20 K	-	189 K	464 K	663 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-21.7 M	-15.3 M	-13.2 M	-	-18 M	-20.6 M	-18.7 M	-	-6.63 M	-6.34 M	-7.1 M	-	-22.7 M	-24.5 M	-18.9 M	-	-8.11 M	-6.46 M	-5.24 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	2.62 M	2.82 M	2.9 M	-	3.11 M	3.23 M	3.75 M	-	47 K	-76 K	-151 K	-	26 K	15 K	18 K	-	-4 K	-4 K	-37 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-21.6 M	-	-13.2 M	-	-17.9 M	-	-18.7 M	-	-6.1 M	-5.91 M	-7.05 M	-	-22.1 M	-24.1 M	-18.7 M	-	-7.66 M	-6.19 M	-5.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	23.8 M	15.8 M	13.2 M	-	18 M	20.6 M	18.7 M	-	6.82 M	6.81 M	7.76 M	-	22.7 M	24.5 M	18.9 M	-	8.11 M	6.46 M	5.24 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	19.3 M	8.94 M	7.96 M	-	15 M	13.3 M	12.2 M	-	2.93 M	2.46 M	2.34 M	-	7.04 M	6.76 M	6.65 M	-	1.91 M	1.34 M	828 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency